Business NewsPR NewsWire • AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain

REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, provided guidance today on 2017 milestones for its...

View More : http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-provides-guidance-on-2017-milestones-for-arx-04-now-known...
Releted News by prnewswire
GAC Motor to host global release of three most anticipated vehicles including blockbuster SUV GS7 at 2017 NAIAS
Nissan Titan Wins TRUCK TREND'S 2017 Pickup Truck of the Year Award
AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
LIMA Inks Exclusive Partnership with UBM for Licensing Expo China
Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook
CompTIA to Launch IT Pro Association to Help Foster Skilled Workforce